Importantly, inhibition of abnormal ribosome biogenesis using drugs that inhibit mTORC1/ribosomal protein S6 (RPS6) signaling is an effective strategy to treat cancer.33 Calvisi et al.34 showed that the activity of mTORC1 and RPS6 is higher in human hepatocellular carcinoma tissue than in the normal liver and promotes tumor progression. Here, RPS6 is linked to cancer.